Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000811652 | SCV000951928 | benign | Tuberous sclerosis 2 | 2024-07-01 | criteria provided, single submitter | clinical testing | |
Human Genome Sequencing Center Clinical Lab, |
RCV000811652 | SCV001435082 | uncertain significance | Tuberous sclerosis 2 | criteria provided, single submitter | clinical testing | ||
Genome- |
RCV000811652 | SCV002040595 | uncertain significance | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002336669 | SCV002638692 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-06-26 | criteria provided, single submitter | clinical testing | The p.C395Y variant (also known as c.1184G>A), located in coding exon 11 of the TSC2 gene, results from a G to A substitution at nucleotide position 1184. The cysteine at codon 395 is replaced by tyrosine, an amino acid with highly dissimilar properties. This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. |